Patent · US Active

Abiraterone prodrugs

US11957696B2 · kind B2 · utility

1Cited by

12References

21Claims

0Family size

Assignee

PROPELLA THERAPEUTICS, INC. · US

Inventors

Matthew J. SHARP · Apex, US
William R. Moore · Pittsboro, US

Key dates

Filing date	Feb 14, 2022
Grant date	Apr 16, 2024
Priority date	—
Expiry date	Feb 14, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.